Multivariate Meta-Analysis: Contributions of Ingram Olkin

A Tribute to Ingram Olkin

It is with pleasure and pride that I introduce this special section in honor of Ingram Olkin. This tribute is especially fitting because, among the many profound and far-reaching contributions that he has made to our profession, Ingram Olkin was the key force behind the genesis of Statistical Science. As put so eloquently by Morrie DeGroot [1], the founding Executive Editor of Statistical Science.

A Conversation with Ingram Olkin

Ingram Olkin was born on July 23, 1924 in Waterbury, Connecticut. His family moved to New York in 1934 and he graduated from DeWitt Clinton High School in 1941. He served three years in the Air Force during World War II and obtained a B.S. in mathematics at the City College of New York in 1947. After receiving an M.A. in mathematical statistics from Columbia in 1949, he completed his graduate studies in the Department of Statistics at the University of North Carolina in 1951. His dissertation was written under the direction of S. N. Roy and Harold Hotelling. He joined the Department of Mathema…

Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions

The COVID-19 pandemic continues to affect the conduct of clinical trials globally. Complications may arise from pandemic-related operational challenges such as site closures, travel limitations and interruptions to the supply chain for the investigational product, or from health-related challenges such as COVID-19 infections. Some of these complications lead to unforeseen intercurrent events in the sense that they affect either the interpretation or the existence of the measurements associated with the clinical question of interest. In this article, we demonstrate how the ICH E9(R1) Addendum o…

[特邀讨论] 应对临床试验中断的随机化检验：NISS英格拉姆·奥尔金论坛系列关于非计划性临床试验中断的报告

[Invited Discussion] Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions

本文是针对Uschner等人关于临床试验中断与随机化检验研究的特邀讨论，指出靶向学习（TL）及其路线图可有效应对存在并发事件的受中断临床试验，要求作者论证随机化检验的唯一有效性。